Italian intersociety consensus on management of long covid in children.
COVID-19
Long COVID
Mental health
Pediatric infectious diseases
SARS-CoV-2
Journal
Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759
Informations de publication
Date de publication:
09 Mar 2022
09 Mar 2022
Historique:
received:
08
12
2021
accepted:
06
02
2022
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
12
3
2022
Statut:
epublish
Résumé
Two sequelae of pediatric COVID-19 have been identified, the multisystem inflammatory syndrome in children (MIS-C) and the long COVID. Long COVID is much less precisely defined and includes all the persistent or new clinical manifestations evidenced in subjects previously infected by SARS-CoV-2 beyond the period of the acute infection and that cannot be explained by an alternative diagnosis. In this Intersociety Consensus, present knowledge on pediatric long COVID as well as how to identify and manage children with long COVID are discussed. Although the true prevalence of long COVID in pediatrics is not exactly determined, it seems appropriate to recommend evaluating the presence of symptoms suggestive of long COVID near the end of the acute phase of the disease, between 4 and 12 weeks from this. Long COVID in children and adolescents should be suspected in presence of persistent headache and fatigue, sleep disturbance, difficulty in concentrating, abdominal pain, myalgia or arthralgia. Persistent chest pain, stomach pain, diarrhea, heart palpitations, and skin lesions should be considered as possible symptoms of long COVID. It is recommended that the primary care pediatrician visits all subjects with a suspected or a proven diagnosis of SARS-CoV-2 infection after 4 weeks to check for the presence of symptoms of previously unknown disease. In any case, a further check-up by the primary care pediatrician should be scheduled 3 months after the diagnosis of SARS-CoV-2 infection to confirm normality or to address emerging problems. The subjects who present symptoms of any organic problem must undergo a thorough evaluation of the same, with a possible request for clinical, laboratory and / or radiological in-depth analysis in case of need. Children and adolescents with clear symptoms of mental stress will need to be followed up by existing local services for problems of this type. Pediatric long COVID is a relevant problem that involve a considerable proportion of children and adolescents. Prognosis of these cases is generally good as in most of them symptoms disappear spontaneously. The few children with significant medical problems should be early identified after the acute phase of the infection and adequately managed to assure complete resolution. A relevant psychological support for all the children during COVID-19 pandemic must be organized by health authorities and government that have to treat this as a public health issue.
Sections du résumé
BACKGROUND
BACKGROUND
Two sequelae of pediatric COVID-19 have been identified, the multisystem inflammatory syndrome in children (MIS-C) and the long COVID. Long COVID is much less precisely defined and includes all the persistent or new clinical manifestations evidenced in subjects previously infected by SARS-CoV-2 beyond the period of the acute infection and that cannot be explained by an alternative diagnosis. In this Intersociety Consensus, present knowledge on pediatric long COVID as well as how to identify and manage children with long COVID are discussed.
MAIN FINDINGS
RESULTS
Although the true prevalence of long COVID in pediatrics is not exactly determined, it seems appropriate to recommend evaluating the presence of symptoms suggestive of long COVID near the end of the acute phase of the disease, between 4 and 12 weeks from this. Long COVID in children and adolescents should be suspected in presence of persistent headache and fatigue, sleep disturbance, difficulty in concentrating, abdominal pain, myalgia or arthralgia. Persistent chest pain, stomach pain, diarrhea, heart palpitations, and skin lesions should be considered as possible symptoms of long COVID. It is recommended that the primary care pediatrician visits all subjects with a suspected or a proven diagnosis of SARS-CoV-2 infection after 4 weeks to check for the presence of symptoms of previously unknown disease. In any case, a further check-up by the primary care pediatrician should be scheduled 3 months after the diagnosis of SARS-CoV-2 infection to confirm normality or to address emerging problems. The subjects who present symptoms of any organic problem must undergo a thorough evaluation of the same, with a possible request for clinical, laboratory and / or radiological in-depth analysis in case of need. Children and adolescents with clear symptoms of mental stress will need to be followed up by existing local services for problems of this type.
CONCLUSIONS
CONCLUSIONS
Pediatric long COVID is a relevant problem that involve a considerable proportion of children and adolescents. Prognosis of these cases is generally good as in most of them symptoms disappear spontaneously. The few children with significant medical problems should be early identified after the acute phase of the infection and adequately managed to assure complete resolution. A relevant psychological support for all the children during COVID-19 pandemic must be organized by health authorities and government that have to treat this as a public health issue.
Identifiants
pubmed: 35264214
doi: 10.1186/s13052-022-01233-6
pii: 10.1186/s13052-022-01233-6
pmc: PMC8905554
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
42Informations de copyright
© 2022. The Author(s).
Références
Eur Respir J. 2022 Feb 3;59(2):
pubmed: 34210789
Lancet Child Adolesc Health. 2021 Jun;5(6):e22-e23
pubmed: 33891880
Clin Exp Allergy. 2021 Sep;51(9):1107-1120
pubmed: 34351016
Psychiatry Res. 2020 Nov;293:113429
pubmed: 32882598
Ital J Pediatr. 2021 Sep 18;47(1):191
pubmed: 34537061
BMJ. 2021 Mar 31;372:n693
pubmed: 33789877
Pragmat Obs Res. 2021 Aug 11;12:93-104
pubmed: 34408531
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 2;106:110171
pubmed: 33186638
J Paediatr Child Health. 2022 Jan;58(1):201-202
pubmed: 34060675
Pediatr Infect Dis J. 2020 Dec;39(12):e458-e459
pubmed: 33003103
Lancet Infect Dis. 2021 Dec 21;:
pubmed: 34951953
Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):913-920
pubmed: 34414470
Lancet Psychiatry. 2021 May;8(5):416-427
pubmed: 33836148
Lancet Child Adolesc Health. 2021 Sep;5(9):677-680
pubmed: 34339624
Acta Paediatr. 2021 Sep;110(9):2578-2580
pubmed: 34157167
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
Nat Med. 2021 Sep;27(9):1607-1613
pubmed: 34163090
Acta Paediatr. 2021 Mar;110(3):914-921
pubmed: 33205450
Pediatr Pulmonol. 2021 Aug;56(8):2495-2502
pubmed: 34102037
Eur Heart J Suppl. 2021 Oct 08;23(Suppl E):E1-E5
pubmed: 34650349
J Paediatr Child Health. 2022 Jan;58(1):46-53
pubmed: 34694037
Pediatr Infect Dis J. 2021 Dec 1;40(12):e509-e511
pubmed: 34371507
Paediatr Drugs. 2021 Mar;23(2):119-129
pubmed: 33479801
JAMA Netw Open. 2021 Oct 1;4(10):e2128568
pubmed: 34643720
Sci Rep. 2021 Jul 5;11(1):13840
pubmed: 34226639
Pediatr Infect Dis J. 2021 Dec 1;40(12):e482-e487
pubmed: 34870392
BMJ Paediatr Open. 2020 Dec 29;4(1):e000905
pubmed: 34192185
Front Pediatr. 2021 Jan 22;8:628072
pubmed: 33553079
Lancet Child Adolesc Health. 2021 Oct;5(10):708-718
pubmed: 34358472
Int J Environ Res Public Health. 2021 Mar 26;18(7):
pubmed: 33810225
Acta Paediatr. 2021 Jul;110(7):2208-2211
pubmed: 33835507
Eur Child Adolesc Psychiatry. 2021 Jan 25;:
pubmed: 33492480
Curr Pediatr Rep. 2021 Oct 19;:1-10
pubmed: 34692237
J Neurol. 2021 Dec;268(12):4915-4917
pubmed: 34674007
Ann Intern Med. 2021 May;174(5):723-725
pubmed: 33284676
Eur J Pediatr. 2021 Feb;180(2):307-322
pubmed: 32803422
Clin Infect Dis. 2021 Dec 6;73(11):e4058-e4063
pubmed: 33252665
BMJ. 2021 Sep 1;374:n2157
pubmed: 34470745
Int J Tuberc Lung Dis. 2020 Oct 1;24(10):1116-1118
pubmed: 33126950
Int J Environ Res Public Health. 2021 Apr 08;18(8):
pubmed: 33917940
MedComm (2020). 2020 Jul 02;:
pubmed: 34172986
JAMA. 2021 Jul 15;:
pubmed: 34264266
Lancet Reg Health Eur. 2021 Sep;8:100186
pubmed: 34386785
MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-998
pubmed: 32730238